Siddharth Turkar

About

Dr. Siddharth W. Turkar, DM (Medical Oncology), is a Senior Consultant Medical Oncologist at Apollo Hospitals, Navi Mumbai, India. His clinical practice focuses on thoracic oncology, breast cancer, gastrointestinal malignancies, hematologic malignancies, precision oncology, immunotherapy, and targeted therapies. His academic interests include clinical trials, real-world evidence, systematic reviews and meta-analyses, artificial intelligence in oncology, and medical education. He has authored peer-reviewed publications, book chapters, and regularly presents research at national and international oncology conferences.

Employment

• Apollo Hospitals, Navi Mumbai Consultant
  2025 - Present
• MMI Narayana Multispeciality Hospital Raipur Consultant
  2019 - 2025
• Tata Memorial Hospital Assistant Professor
  2018 - 2019
• Tata Memorial Hospital Specialist Registrar
  2017 - 2018

Education

• Tata Memorial Hospital DM
  2014 - Present

Projects & Funding

Projects & funding information is unavailable.

Publications (26)

• Multidisciplinary Management of Oligometastatic Breast Cancer
  Apollo Clinical Book Series: Breast Cancer 2026
  +Save
• Neoadjuvant and Adaptive Therapies in Early Breast Cancer: Current Evidence and Pitfalls
  Apollo Clinical Book Series: Breast Cancer 2026
  +Save
• Fibromatosis-like metaplastic carcinoma of the breast: A rare case report
  SOUTH ASIAN JOURNAL OF CANCER 2026 DOI: 10.25259/SAJC_12_2025
  +Save
• ADAPT-T-DXd: Multi-institutional real-world study of dose-adapted trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer.
  Journal of Clinical Oncology 2026 DOI: 10.1200/jco.2026.44.16_suppl.1106
  +Save
• Phase 3 randomized study of physician choice vs metronomic chemotherapy in platinum refractory/ineligible head and neck cancer in palliative setting with survival outcomes
  Cancer Letters 2025 DOI: 10.1016/j.canlet.2025.217702
  +Save
• Breast Cancer
  Tata Memorial Centre Textbook of Oncology 2024 DOI: 10.1007/978-981-99-3378-5_32
  +Save
• Palbociclib: A novel and effective therapy for advanced liposarcoma
  National Medical Journal of India 2024 DOI: 10.25259/NMJI_756_2024
  +Save
• Phase 3 randomized study for evaluation of physician choice Rx and triple metronomic as second-line therapy in head and neck cancer (CRSF 2021-HN-001)
  JOURNAL OF CLINICAL ONCOLOGY 2023
  +Save
• Phase 3 randomized study for evaluation of physician choice Rx and triple metronomic as second-line therapy in head and neck cancer (CRSF 2021-HN-001).
  JOURNAL OF CLINICAL ONCOLOGY 2023 DOI: 10.1200/JCO.2023.41.17_SUPPL.LBA6004
  +Save
• Phase 3 randomized study for evaluation of physician's choice treatment and triple metronomic as second-line therapy in head and neck cancer.
  JOURNAL OF CLINICAL ONCOLOGY 2022
  +Save